Current Report Filing (8-k)
01 March 2023 - 10:59PM
Edgar (US Regulatory)
0001710340 false 0001710340 2023-03-01
2023-03-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
March 1, 2023
Date
of Report (Date of earliest event reported)
ETON PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware |
|
001-38738 |
|
37-1858472 |
|
(State
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
Number)
|
21925 W. Field Parkway,
Suite 235
Deer Park,
Illinois
60010-7208
(Address
of principal executive offices) (Zip code)
(847)
787-7361
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
| |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
|
Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
|
Common Stock, par value $0.001 per share |
|
ETON |
|
NASDAQ Global Market |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
|
Item
5.02. |
Departure
of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers |
Effective
March 1, 2023,
Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) has appointed
David Krempa to the position of Chief Business Officer. Mr. Krempa
previously was employed by the Company in the Position of Senior
Vice President, Business Development and Investor
Relations.
In
connection with the appointment as Chief Business Officer, Mr.
Krempa will receive an annual salary of $385,000 and is eligible
for an annual discretionary bonus as determined by the board of
directors. Mr. Krempa also participates in the Company’s 2018
Equity Incentive Plan along with other officers and employees of
the Company. Mr. Krempa’s employment with the Company is “at will”
and his employment may be terminated by the Company at any time for
any reason or for no reason. In the event Mr. Krempa’s employment
is terminated without “cause” or he terminates his employment for
“good reason,” he will receive six months’ of his base salary as
severance. Further, if such termination occurs within twelve months
of a change in control of the Company, all of Mr. Krempa’s unvested
stock options shall immediately vest.
Mr.
Krempa has been employed full time by the Company since 2017. Prior
to his appointment as Chief Business Officer, he served as Senior
Vice President, Business Development and Investor Relations since
April 2021, Vice President, Business Development from March 2019 to
April 2021, and prior to that he served as Executive Director,
Business Development since September 2017. Mr. Krempa received his
B.S. in Finance from DePaul University.”
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date:
March 1, 2023 |
By: |
/s/
James R. Gruber |
| |
|
James
R. Gruber |
| |
|
Chief
Financial Officer and Secretary |
| |
|
(Principal
Financial Officer) |
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From May 2023 to Jun 2023
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From Jun 2022 to Jun 2023
